Short Interest in Renalytix Plc (NASDAQ:RNLX) Drops By 15.3%

Renalytix Plc (NASDAQ:RNLX) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 673,700 shares, a decrease of 15.3% from the March 31st total of 795,200 shares. Based on an average daily volume of 1,830,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Renalytix

A number of institutional investors have recently modified their holdings of RNLX. Allspring Global Investments Holdings LLC acquired a new stake in shares of Renalytix during the 3rd quarter valued at about $547,000. Pinnacle Associates Ltd. lifted its stake in Renalytix by 7.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 846,534 shares of the company’s stock valued at $330,000 after buying an additional 60,572 shares in the last quarter. Finally, Pentwater Capital Management LP lifted its stake in Renalytix by 5.9% in the 3rd quarter. Pentwater Capital Management LP now owns 598,440 shares of the company’s stock valued at $958,000 after buying an additional 33,440 shares in the last quarter. 9.92% of the stock is currently owned by institutional investors and hedge funds.

Renalytix Trading Up 2.6 %

Shares of RNLX opened at $0.69 on Wednesday. Renalytix has a 12 month low of $0.24 and a 12 month high of $4.04. The stock has a fifty day moving average price of $0.88 and a 200-day moving average price of $0.70. The firm has a market cap of $43.79 million, a PE ratio of -1.54 and a beta of 3.03.

Renalytix (NASDAQ:RNLX) last announced its quarterly earnings results on Wednesday, February 14th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $0.71 million for the quarter, compared to the consensus estimate of $0.70 million. Renalytix had a negative return on equity of 1,008.88% and a negative net margin of 1,736.47%.

Renalytix Company Profile

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.